X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
adult (7) 7
aged (7) 7
female (7) 7
male (7) 7
middle aged (7) 7
chemotherapy (6) 6
index medicus (6) 6
carcinoma, non-small-cell lung - drug therapy (5) 5
lung cancer (5) 5
lung neoplasms - drug therapy (5) 5
care and treatment (4) 4
oncology (4) 4
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
cancer therapies (3) 3
cisplatin - administration & dosage (3) 3
gemcitabine (3) 3
lung cancer, non-small cell (3) 3
medicine, general & internal (3) 3
metastasis (3) 3
mutation (3) 3
abridged index medicus (2) 2
aged, 80 and over (2) 2
antineoplastic agents - therapeutic use (2) 2
biotechnology & applied microbiology (2) 2
cancer patients (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
cisplatin (2) 2
clinical trials (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease-free survival (2) 2
drug dosages (2) 2
drug therapy, combination (2) 2
epidermal growth factor receptors (2) 2
erlotinib (2) 2
gefitinib (2) 2
health aspects (2) 2
kaplan-meier estimate (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - mortality (2) 2
lung neoplasms - pathology (2) 2
metaanalysis (2) 2
non-small cell lung carcinoma (2) 2
nsclc (2) 2
open-label (2) 2
patients (2) 2
prospective studies (2) 2
protein kinase inhibitors - therapeutic use (2) 2
protein-tyrosine kinase (2) 2
quality of life (2) 2
quinazolines - therapeutic use (2) 2
reproducibility of results (2) 2
studies (2) 2
therapy (2) 2
treatment outcome (2) 2
tyrosine (2) 2
1st-line gefitinib (1) 1
1st-line treatment (1) 1
acquired-resistance (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
age (1) 1
amifostine (1) 1
amifostine - administration & dosage (1) 1
amifostine - therapeutic use (1) 1
anemia (1) 1
anthracycline (1) 1
anthracyclines (1) 1
antibody detection (1) 1
antigen (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - economics (1) 1
apoptosis (1) 1
aspartate aminotransferase (1) 1
atezolizumab (1) 1
autoantibodies (1) 1
autoantibodies - blood (1) 1
avidin (1) 1
azd9291 (1) 1
bile duct neoplasms - drug therapy (1) 1
bile duct neoplasms - pathology (1) 1
bile ducts, intrahepatic (1) 1
biomarker (1) 1
biomarkers, tumor - blood (1) 1
biotechnology (1) 1
biotin protein ligase (1) 1
body mass index (1) 1
body weight (1) 1
breast cancer (1) 1
breast-cancer (1) 1
capecitabine (1) 1
carboplatin - administration & dosage (1) 1
carboplatin - adverse effects (1) 1
carboplatin - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | RECEPTOR GENE-MUTATIONS | MEDICINE, GENERAL & INTERNAL | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | NEVER-SMOKERS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S834 - S835
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S834 - S835
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article
Journal of the Medical Association of Thailand, ISSN 0125-2208, 12/2016, Volume 99, Issue 12, pp. 1283 - 1290
Cancer-related malnutrition led to poor outcomes of treatment, decreased functional status, decreased quality of life, and delay treatment. To examine the... 
Chemotherapy | Dietary counseling | Malnutrition | Cancer | Body Mass Index | Body Weight | Prospective Studies | Humans | Middle Aged | Male | Energy Intake | Neoplasms - drug therapy | Neoplasms - therapy | Neoplasms - diet therapy | Quality of Life | Female | Aged | Health Status | Neoplasms - pathology
Journal Article
Journal Article
Journal of the Medical Association of Thailand, ISSN 0125-2208, 01/1998, Volume 81, Issue 1, pp. 36 - 40
Journal Article
Journal of the Medical Association of Thailand, ISSN 0125-2208, 03/2001, Volume 84, Issue 3, pp. 397 - 401
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.